Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Pharmacokinetic modeling of penciclovir and BRL42359 in the plasma and tears of healthy cats to optimize dosage recommendations for oral administration of famciclovir.

Sebbag L, Thomasy SM, Woodward AP, Knych HK, Maggs DJ.

Am J Vet Res. 2016 Aug;77(8):833-45. doi: 10.2460/ajvr.77.8.833.

2.

Clinical and antiviral effect of a single oral dose of famciclovir administered to cats at intake to a shelter.

Litster AL, Lohr BR, Bukowy RA, Thomasy SM, Maggs DJ.

Vet J. 2015 Feb;203(2):199-204. doi: 10.1016/j.tvjl.2014.11.011. Epub 2014 Nov 25.

PMID:
25542064
3.

Pharmacokinetics of famciclovir and penciclovir in tears following oral administration of famciclovir to cats: a pilot study.

Thomasy SM, Covert JC, Stanley SD, Maggs DJ.

Vet Ophthalmol. 2012 Sep;15(5):299-306. doi: 10.1111/j.1463-5224.2011.00984.x. Epub 2012 Feb 16.

PMID:
22339892
4.

Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1.

Thomasy SM, Lim CC, Reilly CM, Kass PH, Lappin MR, Maggs DJ.

Am J Vet Res. 2011 Jan;72(1):85-95. doi: 10.2460/ajvr.72.1.85.

PMID:
21194340
5.

Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis.

Block SL, Yogev R, Waldmeier F, Hamed K.

Pediatr Infect Dis J. 2011 Jun;30(6):525-8. doi: 10.1097/INF.0b013e3182067cee.

PMID:
21178655
6.

A new topical treatment protocol for oral hairy leukoplakia.

Moura MD, Haddad JP, Senna MI, Ferreira e Ferreira E, Mesquita RA.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Nov;110(5):611-7. doi: 10.1016/j.tripleo.2010.05.015. Epub 2010 Sep 1.

PMID:
20813564
7.

Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.

Blumer J, Rodriguez A, Sánchez PJ, Sallas W, Kaiser G, Hamed K.

Antimicrob Agents Chemother. 2010 May;54(5):2032-41. doi: 10.1128/AAC.01508-09. Epub 2010 Feb 16.

8.

Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.

Sáez-Llorens X, Yogev R, Arguedas A, Rodriguez A, Spigarelli MG, De León Castrejón T, Bomgaars L, Roberts M, Abrams B, Zhou W, Looby M, Kaiser G, Hamed K.

Antimicrob Agents Chemother. 2009 May;53(5):1912-20. doi: 10.1128/AAC.01054-08. Epub 2009 Mar 9.

9.

Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance.

Bodsworth N, Fife K, Koltun W, Tyring S, Abudalu M, Prichard M, Hamed K.

Curr Med Res Opin. 2009 Feb;25(2):483-7. doi: 10.1185/03007990802664678 .

10.

Regression of herpes viral infection symptoms using melatonin and SB-73: comparison with Acyclovir.

Nunes Oda S, Pereira Rde S.

J Pineal Res. 2008 May;44(4):373-8. doi: 10.1111/j.1600-079X.2007.00538.x.

PMID:
18410585
11.

Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats.

Thomasy SM, Maggs DJ, Moulin NK, Stanley SD.

Am J Vet Res. 2007 Nov;68(11):1252-8.

PMID:
17975982
12.

Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.

Wald A, Selke S, Warren T, Aoki FY, Sacks S, Diaz-Mitoma F, Corey L.

Sex Transm Dis. 2006 Sep;33(9):529-33.

PMID:
16540883
13.

Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial.

Sacks SL, Aoki FY, Martel AY, Shafran SD, Lassonde M.

Clin Infect Dis. 2005 Oct 15;41(8):1097-104. Epub 2005 Sep 12.

PMID:
16163627
14.

Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients.

Peñuelas I, Mazzolini G, Boán JF, Sangro B, Martí-Climent J, Ruiz M, Ruiz J, Satyamurthy N, Qian C, Barrio JR, Phelps ME, Richter JA, Gambhir SS, Prieto J.

Gastroenterology. 2005 Jun;128(7):1787-95.

PMID:
15940613
15.

Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial.

Shafran SD, Tyring SK, Ashton R, Decroix J, Forszpaniak C, Wade A, Paulet C, Candaele D.

J Clin Virol. 2004 Apr;29(4):248-53.

PMID:
15018852
16.

Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials.

Sarisky RT, Bacon TH, Boon RJ, Duffy KE, Esser KM, Leary J, Locke LA, Nguyen TT, Quail MR, Saltzman R.

Arch Virol. 2003 Sep;148(9):1757-69.

PMID:
14505088
17.

Susceptibility of herpes simplex virus isolates to nucleoside analogues and the proportion of nucleoside-resistant variants after repeated topical application of penciclovir to recurrent herpes labialis.

Shin YK, Weinberg A, Spruance S, Bernard M, Bacon TH, Boon RJ, Levin MJ.

J Infect Dis. 2003 Apr 15;187(8):1241-5. Epub 2003 Mar 26.

PMID:
12696003
18.

Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials.

Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T.

Antimicrob Agents Chemother. 2002 Jul;46(7):2238-43.

19.

Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial.

Lin L, Chen XS, Cui PG, Wang JB, Guo ZP, Lu NZ, Bi ZG, Jia H, Yang XY; Topical Penciclovir Clinical Study Group.

J Dermatolog Treat. 2002 Jun;13(2):67-72.

PMID:
12060504
20.

Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials.

Raborn GW, Martel AY, Lassonde M, Lewis MA, Boon R, Spruance SL; Worldwide Topical Penciclovir Collaborative Study Group.

J Am Dent Assoc. 2002 Mar;133(3):303-9.

PMID:
11934185

Supplemental Content

Loading ...
Support Center